nach oben

Erschienen in:

01.11.2014 | Original article

Older patients with inoperable non-small cell lung cancer

Long-term survival after concurrent chemoradiotherapy

verfasst von: Sabine Semrau, MD, Heike Zettl, MD, Guido Hildebrandt, MD, PhD, Gunther Klautke, MD, Rainer Fietkau, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Considering the various comorbidities associated with aging, the feasibility and usefulness of concurrent chemoradiotherapy (CRT) in older patients with inoperable non-small cell lung cancer (NSCLC) is a controversial issue. Here, we compared the feasibility of CRT and the effects of various comorbidities on the prognosis of a minimally selected population of inoperable NSCLC patients aged 60–77 years.

Patients and methods

The study comprised 161 patients with inoperable NSCLC who received CRT with a target radiation dose greater than 60 Gy and platinum-based chemotherapy from 1998 to 2007. The total population included 69 patients aged 60–69 years and 53 aged 70–77 years. These two age cohorts were included in the study with a follow-up of a median 14.5 months.

Results

The two groups showed no differences in long-term survival, as reflected by the 5-year survival rates of 13.0 ± 4.1 % (60- to 69-year-olds) and 14.4 ± 4.9 % (70- to 77-year-olds). During the treatment phase, the groups were comparable in terms of toxicity and the feasibility of chemotherapy. Compared to patients in their 60s, the septuagenarians had more pulmonary comorbidities (p = 0.02), diabetes mellitus (p = 0.04), cardiac comorbidities (p = 0.08), and previous cancer disease (p = 0.08) that exerted a negative effect on survival. In patients without comorbidities, there were no differences between the age groups.

Conclusion

Age is not a contraindication for concurrent CRT per se, because elderly patients do not have a worse long-term prognosis than younger seniors. However, “elderly patients” (≥ 70–77 years) have more concomitant diseases associated with shorter survival than “moderately aged patients” (≥ 60–69 years).

Fietkau R, Semrau S (2010) Stage III: definitive chemoradiotherapy. Front Radiat Ther Oncol 42:122–134PubMedCrossRef

Ramnath N, Dilling TJ, Harris LJ et al (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e314S–e340S

Goeckenjan G, Sitter H, Thomas M et al (2011) Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society –abridged version. Pneumologie 65:e1–e75CrossRef

Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMed

Curran Jr WJ, Paulus, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460PubMedCentralPubMedCrossRef

Zatloukal P, Petruzelka L, Zemanova M et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46: 87–98PubMedCrossRef

Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne dʼOncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 23:5910–5917PubMedCrossRef

Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190PubMedCrossRef

Lee IH, Hayman JA, Landrum MB et al (2009) Treatment recommendations for locally advanced, non-small-cell lung cancer: the influence of physician and patient factors. Int J Radiat Oncol Biol Phys 74:1376–1384PubMedCentralPubMedCrossRef

10.

Paripati HR, Karlin NJ, Schild SE et al (2012) Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer—a retrospective analysis. J Geriat Oncol 3:104–110CrossRef

11.

Wanders R, Steevens J, Botterweck A et al (2011) Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. Eur J Cancer 47:2691–2697PubMedCrossRef

12.

Pallis AG, Gridelli C, Wedding U et al (2014) Management of elderly patients with NSCLC; updated expertʼs opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol [Epub ahead of print]

13.

Semrau S, Klautke G, Fietkau R (2011) Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases. Int J Radiat Oncol Biol Phys 79:96–104PubMedCrossRef

14.

Atagi S, Kawahara M, Yokoyama A et al (2012) Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomized, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 13:671–678PubMedCrossRef

15.

Langer CJ, Hsu C, Curran WJ et al (2002) Elderly patients with locally advanced non- small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG 9410). Proc Am Soc Clin Oncol 21 [abstract 1193]

16.

De Ruysscher D, Botterweck A, Dirx M et al (2009) Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 20:98–102PubMedCrossRef

17.

Topkan E, Parlak C, Topuk S et al (2013) Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIB non-small cell lung carcinoma: Retrospective analysis of 89 patients. Lung Cancer 81:226–230PubMedCrossRef

18.

Schild SE, Stella PJ, Geyer SM et al (2003) The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21:3201–3206PubMedCrossRef

19.

De Ruysscher D, Van Meerbeeck J, Vandecasteele K et al (2012) Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor? Strahlenther Onkol 188:564–567PubMedCrossRef

20.

Huber RM, Engel-Riedel W, Kollmeier J et al (2012) GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase III study. Proc Am Soc Clin Oncol 31 [abstract 7001]

21.

Guckenberger M, Kavanagh A, Partridge M (2012) Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer. Strahlenther Onkol 188:894–900PubMedCrossRef

Titel: Older patients with inoperable non-small cell lung cancer
Long-term survival after concurrent chemoradiotherapy
verfasst von: Sabine Semrau, MD
Heike Zettl, MD
Guido Hildebrandt, MD, PhD
Gunther Klautke, MD
Rainer Fietkau, MD, PhD
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 12/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0710-5

Springer Medizin

Older patients with inoperable non-small cell lung cancer

Long-term survival after concurrent chemoradiotherapy